Chimerix (NASDAQ:CMRX) Share Price Passes Below 200 Day Moving Average of $0.96

Chimerix, Inc. (NASDAQ:CMRX)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.96 and traded as low as $0.86. Chimerix shares last traded at $0.86, with a volume of 86,431 shares traded.

Analyst Ratings Changes

Several research firms recently weighed in on CMRX. Wedbush reiterated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research report on Wednesday, August 14th. Finally, StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Trading Down 1.6 %

The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $0.96. The company has a market capitalization of $77.48 million, a P/E ratio of -0.93 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter last year, the company earned ($0.21) earnings per share. Equities research analysts anticipate that Chimerix, Inc. will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Pale Fire Capital SE increased its position in shares of Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 112,318 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Chimerix during the fourth quarter worth approximately $1,348,000. Acadian Asset Management LLC raised its stake in shares of Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after acquiring an additional 291,981 shares during the last quarter. Koshinski Asset Management Inc. acquired a new position in shares of Chimerix in the 1st quarter worth approximately $42,000. Finally, Marshall Wace LLP bought a new stake in Chimerix during the 2nd quarter worth approximately $137,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.